Abstract: The invention relates to monoclonal antibodies against a tumor-associated antigen which is mainly derived from tumors from the group of carcinomas of the breast, ovaries and prostate, as well as adenocarcinomas of the lung, which additionally react with polymorphic epithelial mucin (PEM), to the preparation and use thereof and to the use of the epitope defined by the antibody for diagnosis and therapy.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
December 9, 1997
Assignee:
Behringwerke Aktiengesellschaft
Inventors:
Klaus Bosslet, Peter Pfleiderer, Gerhard Seemann
Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 .ANG. as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
December 2, 1997
Assignee:
Protein Design Labs, Inc.
Inventors:
Cary L. Queen, William P. Schneider, Harold E. Selick
Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 .ANG. as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
December 2, 1997
Assignee:
Protein Design Labs, Inc.
Inventors:
Cary L. Queen, Man Sung Co, William P. Schneider, Nicholas F. Landolfi, Kathleen L. Coelingh, Harold E. Selick
Abstract: Live or modified live PRRS vaccines for administration to swine are provided which are of low virulence and confer effective immunity against PRRS. The preferred vaccines include virus isolates having average plaque diameters of less than about 2 mm and low pathogenicity. A preferred vaccine includes a small plaque diameter strain, ATCC Accession No. VR2509. The vaccines of the invention may be administered to breeding females or gilts and to weaned piglets, and is effective to immunize the swine against both the respiratory and reproductive forms of the disease.
Abstract: Immunization of animals with a composition containing either an amino acid sequence from the catalytic domain of glucosyltransferase, an amino acid sequence from the glucan-binding region of glucosyltransferase or an amino acid sequence from the native surface domain of glucosyltransferase provoke antibody and T-cell immune responses to this enzyme. Since this enzyme has been implicated in the colonization of mutans streptococci on tooth surfaces, such immune responses are important for the prevention of dental caries. Multicomponent and multivalent compositions which include these amino acid sequences provide effective vaccine capabilities.
Abstract: The use of interacting polymers and oligomers to selectively target compounds to desired sites, in-vitro and in-vivo, wherein the first polymer or oligomer is bound to a targeting agent and the second polymer or oligomer is bound to an active agent, such as a drug, a metal or a radioisotope.
Abstract: A chimeric antibody-agent conjugate for targeting foci of leukocyte accretion comprises a recombinant chimera having an antigen-binding hypervariable region which binds specifically to granulocytes, and a constant region of a human immunoglobulin having an Fc portion with high affinity for receptors on human mononuclear lymphoid cells, said chimera being conjugated to at least one diagnostic agent or therapeutic agent.A method for targeting an imaging or therapy agent to an inflammatory or infectious lesion comprises injecting a mammal parenterally with an effective amount for targeting of the above chimeric anti-leukocyte conjugate.
Abstract: A deletion mutant of bovine herpesvirus type 1 which has a deletion in the glycoprotein gE-gene and which may further have a deletion in the thymidine kinase gene and/or the glycoprotein gI-gene, or have an insertion of a heterologous gene is disclosed. Recombinant nucleic acids which encode the gE-gene or a part thereof are also disclosed, in addition to vaccines and a method of treatment.
Type:
Grant
Filed:
December 6, 1993
Date of Patent:
October 14, 1997
Assignee:
Stichting Centraal Diergeneeskundig Instituut
Inventors:
Franciscus Antonius Maria Rijsewijk, Johannes Theodorus van Oirschot, Roger Kamiel Maes
Abstract: The invention relates to polynucleotides encoding the BW 835 variable domain of an antibody against a tumor-associated antigen which is mainly derived from tumors from the group of carcinomas of the breast, ovaries and prostate, as well as adenocarcinomas of the lung, which additionally react with polymorphic epithelial mucin (PEM), and expression vectors containing the polynucleotides.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
October 7, 1997
Assignee:
Behringwerke Aktiengesellschaft
Inventors:
Klaus Bosslet, Peter Pfleiderer, Gerhard Seemann
Abstract: Antibodies which recognize and bind to histidine rich protein II of Plasmodium falciparum. These antibodies exhibit improved specificity and affinity for the antigen which provides enhanced sensitivity in immunoassays. Peptides useful for generation of the antibodies are also provided.
Type:
Grant
Filed:
March 21, 1995
Date of Patent:
September 9, 1997
Assignee:
Becton, Dickinson and Company
Inventors:
S. Melissa Maret, Hans H. Feindt, Gerald DeWayne Hahn, Keith Uithoven
Abstract: DNA molecules, expression vectors, recombinant host cells and the process of preparing antigenized antibodies which have, inserted within their third complementarity determining regions, antigenic epitopes not found in immunoglobulin molecules are described.
Abstract: The present invention relates to a stabilized protein composition comprising a monomeric protein and a storage-stabilizing amount of sucrose, histidine or glycine, which is sufficient to inhibit aggregation of the protein molecules during freeze/thaw cycles, and methods therefor. More particularly, this invention relates to pharmaceutically-acceptable, single-chain antigen-binding protein compositions having increased frozen-storage stability, especially to freeze/thaw cycles.
Abstract: The DNA encoding an antibody with an altered function, e.g. altered affinity for an effector ligand such as Fc receptor (FcR) on a cell or the Cl component of complement is produced by replacing the nucleic acid encoding at least one amino acid residue in the constant portion of the antibody with nucleic acid encoding a different residue.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
July 15, 1997
Assignee:
Scotgen Biopharmaceuticals Incorporated
Inventors:
Gregory Paul Winter, Alexander Robert Duncan, Dennis Raymond Burton
Abstract: The present invention provides a novel anti-AIDS immunotoxin. The immunotoxin comprises a toxin chemically conjugated to a monoclonal antibody directed against vital reverse transcriptase. Also provided are various methods of using this novel including methods of treating various diseases.
Abstract: A method for controlling infectious diseases in fish and other aquatic lifeforms, regardless of their developmental stage. The method of controlling pathogenic organisms detrimental to aquatic lifeforms includes steps of adding fish which are pre-immunized against one or more organisms pathogenic to fish to the same aquatic medium and with normal fish. The pre-immunized fish continuously and increasingly release antibodies against the pathogenic organisms into the same aquatic medium and can protect or prevent naive (normal, non-infected) fish or naive aquatic lifeforms from infection and are able to enhance the recovery of infected fish or any aquatic lifeforms infected with the same diseases.
Abstract: A process for purifying an antibody is provided. In this process, a mixture containing the antibody and contaminant is subjected to low pH hydrophobic interaction chromatography (LPHIC) optionally at low salt concentration. The antibody is eluted from the column in the fraction which does not bind thereto. This process can be preceded and followed by other purification steps.
Type:
Grant
Filed:
April 20, 1995
Date of Patent:
June 24, 1997
Assignee:
Genentech, Inc.
Inventors:
Ernst H. Rinderknecht, Gerardo A. Zapata
Abstract: The invention relates to monoclonal antibodies against a tumor-associated antigen which is mainly derived from tumors from the group of carcinomas of the breast, ovaries and prostate, as well as adenocarcinomas of the lung, which additionally react with polymorphic epithelial mucin (PEM), to the preparation and use thereof and to the use of the epitope defined by the antibody for diagnosis and therapy.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
June 17, 1997
Assignee:
Behringwerke Aktiengesellschaft
Inventors:
Klaus Bosslet, Peter Pfleiderer, Gerhard Seemann
Abstract: An attenuated poliovirus in which the 5' non-coding region of the genome is:(a) the 5' non-coding region of poliovirus type 3 Leon strain modified by the provision of the bases uracil and adenine at positions 472 and 537 thereof respectively, or(b) the 5' non-coding region of another poliovirus modified by the provision of the bases uracil and adenine at respective positions corresponding to position 472 and 537 of the 5' non-coding region of poliovirus type 3 Leon strain.
Type:
Grant
Filed:
May 9, 1994
Date of Patent:
June 17, 1997
Assignee:
British Technology Group Limited
Inventors:
Andrew Joseph MacAdam, Philip David Minor, David Michael Stone, Jeffrey William Almond
Abstract: The invention relates to a method for providing, via resurfacing, humanized rodent antibodies that have improved therapeutic efficacy due to the presentation of a human surface in the variable region.
Type:
Grant
Filed:
September 9, 1992
Date of Patent:
June 17, 1997
Assignee:
Immunogen Inc.
Inventors:
Jan T. Pedersen, Stephen M. J. Searle, Anthony R. Rees, Michael A. Roguska, Braydon C. Guild
Abstract: A chimeric antibody-agent conjugate for targeting foci of leukocyte accretion comprises a recombinant chimera having an antigen-binding hypervariable region which binds specifically to granulocytes, and a constant region of a human immunoglobulin having an Fc portion with high affinity for receptors on human mononuclear lymphoid cells, said chimera being conjugated to at least one diagnostic agent or therapeutic agent.A method for targeting an imaging or therapy agent to an inflammatory or infectious lesion comprises injecting a mammal parenterally with an effective amount for targeting of the above chimeric anti-leukocyte conjugate.